

Public Dashboard

Reporting Period: January 2024 - December 2024 (Current Period); January 2023 – December 2023 (Prior Period)

Includes all covered plan participants (Active, Non-Medicare Retirees and Medicare Retirees) unless otherwise noted




Table of Contents

- Page 3 Enrollment (Actives)
- Page 4 Enrollment (Retirees)
- Page 5 Plan Paid By Setting
- Page 9 Plan Paid By Age Band and Gender
- Page 13 Emergency Room Visits
- Page 17 Top 15 Drugs
- Page 21 Top 15 Prescription Drug Disease Indications
- Page 25 Top 15 Diagnosis Categories for Medical Claims
- Page 29 Distribution of Claims By Membership



Enrollment: Actives *January* 2024 – *December* 2024

Average Employee and Dependent Counts



Average Employee and Dependent Counts

Line of Business	Employee Count	Dependent Count	Total Count	PEPM ¹
Partnership	26,753	33,465	60,217	\$1,746.96 ²
State	50,580	68,956	119,536	\$1,629.06
Total	77,333	102,420	179,753	\$1,669.84




¹ Per Employee Per Month

² Partnership is higher due to membership located in counties that have a higher average cost of care, Regional pricing adjustments account for this disparity.

Enrollment: Retirees January 2024 – December 2024

Average Retiree and Dependent Counts



Average Retiree and Dependent Counts

Status	Retiree Count	Dependent Count	Total Count	PEPM ¹
Non-Medicare Retirees	16,679	15,428	32,107	\$1,813
Medicare Retirees	44,343	15,991	60,334	\$1,532





Plan Paid By Setting – State Plan Active Population

January 2024 – December 2024 (Current Period); January 2023 – December 2023 (Prior Period)



Total: **Prior – \$1.07B Current – \$1.24B**








Plan Paid By Setting – State Plan Non-Medicare Retirees


January 2024 – December 2024 (Current Period); January 2023 – December 2023 (Prior Period)





Plan Paid By Setting – State Plan Medicare Retirees


January 2024 – December 2024 (Current Period); January 2023 – December 2023 (Prior Period)






Plan Paid By Setting — Partnership Plan (includes retirees)

January 2024 – December 2024 (Current Period); January 2023 – December 2023 (Prior Period)






Plan Paid By Age and Gender – State Plan Active Population *January* 2024 – *December* 2024







Plan Paid By Age and Gender – State Plan Non-Medicare *January* 2024 – *December* 2024



Plan Paid By Age and Gender – State Plan Medicare Retirees *January* 2024 – *December* 2024



Plan Paid By Age and Gender — Partnership Plan (incl. retirees) January 2024 — December 2024







Emergency Room Visits - State Plan Active Population

January 2024 – December 2024 (Current Period); January 2023 – December 2023 (Prior Period)

ER Visits Per Month



State Fiscal Year	Total ER Visits	Visits per 1,000 Covered Lives
Current	35,247	295
Prior	31,288	270







Emergency Room Visits - State Plan Non-Medicare Retirees

January 2024 – December 2024 (Current Period); January 2023 – December 2023 (Prior Period)

ER Visits Per Month



State Fiscal Year	Total ER Visits	Visits per 1,000 Covered Lives
Current	11,050	344
Prior	11,564	334






Emergency Room Visits - State Plan Medicare Retirees

January 2024 – December 2024 (Current Period); January 2023 – December 2023 (Prior Period)

ER Visits Per Month



State Fiscal		Visits per 1,000
Year	Total ER Visits	Covered Lives
Current	30,755	510
Prior	31,262	526







Emergency Room Visits - Partnership Plan (includes retirees)

January 2024 – December 2024 (Current Period); January 2023 – December 2023 (Prior Period)

ER Visits Per Month



State Fiscal Year	Total ER Visits	Visits per 1,000 Covered Lives
Current	17,501	276
Prior	16,689	268





Top 15 Drugs – State Plan Active Population January 2024 – December 2024 By Plan Paid

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	OZEMPIC	Diabetes	\$16,789,444	35,915	\$467
2	DUPIXENT	Skin Disorders	\$9,317,883	4,018	\$2,319
3	MOUNJARO	Diabetes	\$8,225,633	18,404	\$447
4	SKYRIZI	Psoriasis	\$8,184,647	871	\$9,397
5	STELARA	Psoriasis	\$5,625,623	825	\$6,819
6	TRIKAFTA	Cystic Fibrosis	\$4,975,210	228	\$21,821
7	STRENSIQ	Rare Disorders	\$4,887,827	51	\$95,840
8	VYVANSE	ADHD/Narcolepsy	\$3,274,782	7,822	\$419
9	RINVOQ	Autoimmune Disease	\$2,648,691	797	\$3,323
10	XOLAIR	Asthma/COPD	\$2,555,486	1,113	\$2,296
11	VERZENIO	Oncology	\$2,474,284	235	\$10,529
12	PAXLOVID	Viral Infections	\$2,471,709	2,384	\$1,037
13	HUMIRA PEN	Autoimmune Disease	\$2,404,837	917	\$2,623
14	BIKTARVY	Viral Infections/HIV AIDS	\$2,141,055	721	\$2,970
15	VRAYLAR	Mental Health/Neurological Disorders	\$2,136,670	1,374	\$1,555

Top 15 Drugs – State Plan Non-Medicare Retirees January 2024 – December 2024 By Plan Paid

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	OZEMPIC	Diabetes	\$6,066,763	12,343	\$492
2	MOUNJARO	Diabetes	\$2,933,447	6,262	\$468
3	DUPIXENT	Skin Disorders	\$2,683,758	1,161	\$2,312
4	SKYRIZI	Psoriasis	\$2,668,397	256	\$10,423
5	STELARA	Psoriasis	\$1,468,035	219	\$6,703
6	TRIKAFTA	Cystic Fibrosis	\$1,356,307	71	\$19,103
7	XOLAIR	Asthma/COPD	\$1,263,418	512	\$2,468
8	BIKTARVY	Viral Infections/HIV AIDS	\$1,037,007	344	\$3,015
9	VERZENIO	Oncology	\$1,014,393	103	\$9,848
10	OTEZLA	Autoimmune Disease	\$993,434	443	\$2,243
11	JARDIANCE	Diabetes	\$942,685	3,077	\$306
12	ELIQUIS	Blood Disorders	\$927,617	1,904	\$487
13	PAXLOVID	Viral Infections	\$911,595	896	\$1,017
14	VYVANSE	ADHD/Narcolepsy	\$793,332	1,846	\$430
15	VRAYLAR	Mental Health/Neurological Disorders	\$787,680	495	\$1,591

Top 15 Drugs – State Plan Medicare Retirees January 2024 – December 2024 By Plan Paid

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	ELIQUIS	Blood Disorders	\$39,840,051	30,203	\$1,319
2	OZEMPIC	Diabetes	\$34,166,411	20,191	\$1,692
3	JARDIANCE	Diabetes	\$20,533,229	12,634	\$1,625
4	VYNDAMAX	Cardiovascular/Heart Disease	\$15,153,428	297	\$51,022
5	HUMIRA PEN	Autoimmune Disease	\$14,472,302	1,033	\$14,010
6	MOUNJARO	Diabetes	\$14,001,650	8,859	\$1,581
7	REVLIMID	Oncology	\$13,070,741	536	\$24,386
8	XARELTO	Blood Disorders	\$12,586,838	8,484	\$1,484
9	DUPIXENT	Skin Disorders	\$12,121,827	2,433	\$4,982
10	TRELEGY ELLIPTA	Asthma/COPD	\$10,003,423	8,553	\$1,170
11	STELARA	Psoriasis	\$9,744,506	328	\$29,709
12	SKYRIZI	Psoriasis	\$9,319,479	371	\$25,120
13	FARXIGA	Diabetes	\$9,055,908	5,900	\$1,535
14	JANUVIA	Diabetes	\$8,997,430	5,760	\$1,562
15	XTANDI	Oncology	\$8,749,475	460	\$19,021

Top 15 Drugs – Partnership Plan (includes retirees) January 2024 – December 2024 By Plan Paid

Rank	Drug	Disease Indication	Total Plan Paid	Script Count	Cost Per Script
1	OZEMPIC	Diabetes	\$7,889,574	14,403	\$548
2	DUPIXENT	Skin Disorders	\$4,931,551	1,936	\$2,547
3	MOUNJARO	Diabetes	\$4,025,065	7,548	\$533
4	STELARA	Psoriasis	\$3,566,738	411	\$8,678
5	SKYRIZI	Psoriasis	\$3,276,164	333	\$9,838
6	ELIQUIS	Blood Disorders	\$2,923,510	3,671	\$796
7	HUMIRA PEN	Autoimmune Disease	\$2,242,519	509	\$4,406
8	JARDIANCE	Diabetes	\$1,890,316	3,511	\$538
9	XTANDI	Oncology	\$1,700,065	120	\$14,167
10	RINVOQ	Autoimmune Disease	\$1,607,369	453	\$3,548
11	REVLIMID	Oncology	\$1,469,608	98	\$14,996
12	ENBREL SURECLICK	Autoimmune Disease	\$1,417,239	387	\$3,662
13	PAXLOVID	Viral Infections	\$1,402,060	1,289	\$1,088
14	VYVANSE	ADHD/Narcolepsy	\$1,386,434	3,655	\$379
15	ENTRESTO	Cardiovascular/Heart Disease	\$1,237,771	1,024	\$1,209



Top 15 Prescription Drug Disease Indications State Plan Active Population

Rank	Disease Indication	Plan Paid	Script Count	Cost Per Script
1	Diabetes	\$32,523,631	100,876	\$322
2	Oncology	\$20,344,273	6,454	\$3,152
3	Psoriasis	\$19,104,385	4,622	\$4,133
4	Autoimmune Disease	\$18,864,734	8,812	\$2,141
5	Skin Disorders	\$14,388,117	63,661	\$226
6	ADHD/Narcolepsy	\$10,739,201	54,252	\$198
7	Asthma/COPD	\$9,693,928	64,604	\$150
8	Multiple Sclerosis/Neuromuscular Disorders	\$9,157,126	1,607	\$5,698
9	Rare Disorders	\$7,010,811	1,563	\$4,485
10	Viral Infections/HIV AIDS	\$6,339,092	3,659	\$1,732
11	Migraine	\$5,665,183	20,902	\$271
12	Cystic Fibrosis	\$5,556,182	359	\$15,477
13	Mental Health/Neurological Disorders	\$5,127,993	15,274	\$336
14	Depression	\$5,042,679	95,899	\$53
15	Blood Disorders	\$4,873,654	9,071	\$537



Top 15 Prescription Drug Disease Indications State Plan Non-Medicare Retirees

Disease Indication	Plan Paid	Script Count	Cost Per Script
Diabetes	\$13,756,651	41,916	\$328
Oncology	\$8,495,080	3,008	\$2,824
Autoimmune Disease	\$7,563,317	3,600	\$2,101
Psoriasis	\$5,901,307	1,395	\$4,230
Skin Disorders	\$4,394,668	20,881	\$210
Asthma/COPD	\$4,310,026	22,218	\$194
Multiple Sclerosis/Neuromuscular Disorders	\$3,065,915	694	\$4,418
ADHD/Narcolepsy	\$2,651,850	11,948	\$222
Viral Infections/HIV AIDS	\$2,480,799	1,227	\$2,022
Blood Disorders	\$2,452,060	5,301	\$463
Lipid/Cholesterol Disorders	\$2,334,136	39,643	\$59
Depression	\$2,224,836	34,851	\$64
Vaccines/Immunizing Agents	\$1,941,880	14,269	\$136
Seizure Disorder	\$1,941,658	16,159	\$120
Mental Health/Neurological Disorders	\$1,857,445	5,960	\$312
	Diabetes Oncology Autoimmune Disease Psoriasis Skin Disorders Asthma/COPD Multiple Sclerosis/Neuromuscular Disorders ADHD/Narcolepsy Viral Infections/HIV AIDS Blood Disorders Lipid/Cholesterol Disorders Depression Vaccines/Immunizing Agents Seizure Disorder	Diabetes \$13,756,651 Oncology \$8,495,080 Autoimmune Disease \$7,563,317 Psoriasis \$5,901,307 Skin Disorders \$4,394,668 Asthma/COPD \$4,310,026 Multiple Sclerosis/Neuromuscular Disorders \$3,065,915 ADHD/Narcolepsy \$2,651,850 Viral Infections/HIV AIDS \$2,480,799 Blood Disorders \$2,452,060 Lipid/Cholesterol Disorders \$2,334,136 Depression \$2,224,836 Vaccines/Immunizing Agents \$1,941,880 Seizure Disorder \$1,941,658	Diabetes \$13,756,651 41,916 Oncology \$8,495,080 3,008 Autoimmune Disease \$7,563,317 3,600 Psoriasis \$5,901,307 1,395 Skin Disorders \$4,394,668 20,881 Asthma/COPD \$4,310,026 22,218 Multiple Sclerosis/Neuromuscular Disorders \$3,065,915 694 ADHD/Narcolepsy \$2,651,850 11,948 Viral Infections/HIV AIDS \$2,480,799 1,227 Blood Disorders \$2,452,060 5,301 Lipid/Cholesterol Disorders \$2,334,136 39,643 Depression \$2,224,836 34,851 Vaccines/Immunizing Agents \$1,941,880 14,269 Seizure Disorder \$1,941,658 16,159

Top 15 Prescription Drug Disease Indications State Plan Medicare Retirees

Rank	Disease Indication	Plan Paid	Script Count	Cost Per Script
1	Diabetes	\$123,865,671	125,304	\$989
2	Oncology	\$108,033,903	14,347	\$7,530
3	Blood Disorders	\$61,265,059	56,771	\$1,079
4	Autoimmune Disease	\$48,681,319	7,108	\$6,849
5	Asthma/COPD	\$33,036,568	79,607	\$415
6	Psoriasis	\$31,573,031	2,124	\$14,865
7	Cardiovascular/Heart Disease	\$30,639,163	22,929	\$1,336
8	Vaccines/Immunizing Agents	\$24,814,137	77,234	\$321
9	Skin Disorders	\$16,418,332	44,169	\$372
10	Multiple Sclerosis/Neuromuscular Disorders	\$13,237,057	1,279	\$10,350
11	Overactive Bladder/Urinary Incontinence	\$11,776,344	18,663	\$631
12	Lipid/Cholesterol Disorders	\$11,765,433	190,090	\$62
13	Rare Disorders	\$8,508,423	3,331	\$2,554
14	Lung Disease	\$7,860,669	479	\$16,411
15	Anti-Infectives	\$7,654,074	113,969	\$67

Top 15 Prescription Drug Disease Indications Partnership Plan (includes retirees)

Rank	Disease Indication	Plan Paid	Script Count	Cost Per Script
1	Diabetes	\$20,011,389	49,463	\$405
2	Oncology	\$19,064,212	4,725	\$4,035
3	Autoimmune Disease	\$13,141,684	5,080	\$2,587
4	Psoriasis	\$10,121,022	2,143	\$4,723
5	Skin Disorders	\$7,448,235	32,208	\$231
6	Asthma/COPD	\$6,291,676	32,701	\$192
7	Blood Disorders	\$4,998,314	8,848	\$565
8	Vaccines/Immunizing Agents	\$4,875,185	22,800	\$214
9	ADHD/Narcolepsy	\$4,733,869	26,798	\$177
10	Cardiovascular/Heart Disease	\$4,270,171	3,596	\$1,187
11	Rare Disorders	\$4,183,775	1,038	\$4,031
12	Multiple Sclerosis/Neuromuscular Disorders	\$3,478,560	848	\$4,102
13	Mental Health/Neurological Disorders	\$2,676,425	8,155	\$328
14	Viral Infections/HIV AIDS	\$2,643,949	1,659	\$1,594
15	Depression	\$2,477,485	55,218	\$45

Top 15 Medical Diagnosis Categories State Plan Active Population

Rank	Diagnosis Description	Plan Paid
1	Encounter for other aftercare and medical care	\$ 37,646,603.88
2	Encounter for screening for malignant neoplasms	\$ 30,258,764.24
3	Encounter for general examination without complaint, suspected or reported diagnosis	\$ 24,363,948.57
4	Multiple sclerosis	\$ 17,616,955.16
5	Dorsalgia	\$ 16,956,732.09
6	Other anxiety disorders	\$ 16,135,389.39
7	Major depressive disorder, recurrent	\$ 13,917,745.15
8	Liveborn infants according to place of birth and type of delivery	\$ 13,493,762.51
9	Pervasive developmental disorders	\$ 12,896,055.82
10	Other joint disorder, not elsewhere classified	\$ 12,578,509.37
11	Reaction to severe stress, and adjustment disorders	\$ 12,210,771.34
12	Sleep disorders	\$ 11,084,231.67
13	Alcohol related disorders	\$ 10,727,042.16
14	Encounter for other special examination without complaint, suspected or reported diagnosis	\$ 10,665,809.45
15	Osteoarthritis of knee	\$ 10,395,226.69
		L

¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.

²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.



Top 15 Medical Diagnosis Categories State Plan Non-Medicare Retirees

Rank	Diagnosis Description	Plan Paid
1	Encounter for other aftercare medical care	\$ 23,588,984.51
2	Encounter for screening for malignant neoplasms	\$ 12,958,347.14
3	Other Sepsis	\$ 6,855,347.50
4	Osteoarthritis of knee	\$ 6,607,512.97
5	Dorsalgia	\$ 6,024,791.18
6	Encounter for general examination without complaint, suspected or reported diagnosis	\$ 5,823,692.33
7	Atrial fibrillation and flutter	\$ 5,429,045.20
8	Osteoarthritis of hip	\$ 5,210,508.96
9	Other joint disorder, not elsewhere classified	\$ 4,823,639.89
10	Alcohol related disorders	\$ 4,695,606.36
11	Multiple sclerosis	\$ 4,600,533.75
12	Sleep disorders	\$ 4,432,761.45
13	Major depressive disorder, recurrent	\$ 4,296,679.55
14	Chronic ischemic heart disease	\$ 4,185,906.78
15	Malignant neoplasm of prostate	\$ 3,849,169.58

¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.

²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.



Top 15 Medical Diagnosis Categories State Plan Medicare Retirees

Rank	Diagnosis Description	Plan Paid
1	Encounter for other aftercare and medical care	\$ 41,229,498.32
2	Other sepsis	\$ 24,146,949.62
3	Osteoarthritis of knee	\$ 15,731,668.72
4	Atrial fibrillation and flutter	\$ 15,143,121.32
5	Type 2 diabetes mellitus	\$ 14,642,521.50
6	Other retinal disorders	\$ 12,880,509.67
7	Chronic kidney disease (CKD)	\$ 12,072,020.86
8	Dorsalgia	\$ 11,360,486.24
9	Chronic ischemic heart disease	\$ 10,182,258.90
10	Encounter for screening for malignant neoplasms	\$ 10,133,422.96
11	Other spondylopathies	\$ 10,076,257.80
12	Age-related cataract	\$ 9,633,937.47
13	Other joint disorder, not elsewhere classified	\$ 9,083,628.51
14	Encounter for general examination without complaint, suspected or reported diagnosis	\$ 8,873,696.39
15	Fracture of femur	\$ 8,705,016.72
		_

¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.

²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.



Top 15 Medical Diagnosis Categories Partnership Plan (includes retirees)

Rank	Diagnosis Description	Plan Paid
1	Encounter for other aftercare and medical care	\$ 25,006,103.54
2	Encounter for screening for malignant neoplasms	\$ 16,151,116.23
3	Encounter for general examination without complaint, suspected or reported diagnosis	\$ 13,294,298.40
4	Liveborn infants according to place of birth and type of delivery	\$ 12,743,374.94
5	Other anxiety disorders	\$ 8,877,194.69
6	Multiple sclerosis	\$ 8,679,828.96
7	Dorsalgia	\$ 8,588,595.73
8	Other sepsis	\$ 8,568,668.14
9	Other joint disorder, not elsewhere classified	\$ 6,494,070.13
10	Malignant neoplasm of breast	\$ 6,370,472.00
11	Osteoarthritis of knee	\$ 6,367,417.28
12	Reaction to severe stress, and adjustment disorders	\$ 5,818,113.84
13	Encounter for other special examination without complaint, suspected or reported diagnosis	\$ 5,764,495.30
14	Major depressive disorder, recurrent	\$ 5,625,840.16
15	Atrial fibrillation and flutter	\$ 5,045,475.63


¹This category captures admissions for cancer treatment, including chemotherapy, immunotherapy, and radiation therapy, as well as monitoring certain drug levels for patients on long-term drug therapy.

²This category captures routine physicals, well-child visits, and other general health examinations in patients who are currently not symptomatic.

As Partnership retiree membership increases, they will be reported separately.




January 2024 – December 2024 By Plan Paid–State Plan Active Population






January 2024 – December 2024 By Plan Paid-State Plan Non-Medicare Population





January 2024 – December 2024 By Plan Paid–State Plan Medicare Population





January 2024 – December 2024 By Plan Paid–Partnership Plan (includes retirees)

